Cancer Res Treat.  2012 Dec;44(4):271-274.

Poorly Differentiated Neuroendocrine Carcinoma in a Perigastric Lymph Node from an Unknown Primary Site

• Lee HS
• Han HS
• Lim SN
• Jeon HJ
• Lee HC
• Lee OJ
• Yun HY
• Lee KH
• Kim ST

Abstract

Neuroendocrine carcinomas from an unknown primary site are uncommon. The authors report on a case of neuroendocrine carcinoma in a perigastric lymph node (LN) with no primary site. A 52-year-old male patient with early gastric adenocarcinoma underwent treatment by endoscopic submucosal dissection, and, six months later, findings on a computed tomographic scan of the abdomen revealed a LN enlargement measuring 2.0 cm in the perigastric region. The patient underwent subtotal gastrectomy and regional LN dissection under a suggestive preoperative diagnosis of gastric adenocarcinoma with LN metastasis. However, microscopically, no residual tumor was found in the stomach, and the perigastric LN showed poorly differentiated neuroendocrine carcinoma (PDNEC). After an extensive workup, no primary site was identified. The patient also received four cycles of etoposide and cisplatin. Despite its extremely rare incidence, this case suggests that PDNEC of an unknown primary site is limited to a single site, and that resection should be considered in combination with chemotherapy.

Keyword

Lymph nodes; Neuroendocrine carcinoma; Unknown primary neoplasms

MeSH Terms

Abdomen
Adenocarcinoma
Carcinoma, Neuroendocrine
Cisplatin
Etoposide
Gastrectomy
Humans
Incidence
Lymph Nodes
Male
Neoplasm Metastasis
Neoplasm, Residual
Neoplasms, Unknown Primary
Stomach
Cisplatin
Etoposide

Figure

• 

  Fig. 1 (A) Resected specimen of type IIc early gastric cancer obtained by endoscopic submucosal dissection. (B) Histologic examination revealed well differentiated adenocarcinoma restricted to the mucosa without lymphovascular invasion or perineural invasion (H&E staining, ×100).

• 

  Fig. 2 Computed tomograph of the abdomen showing lymph node enlargement in the perigastric area.

• 

  Fig. 3 Microscopic examination of the perigastric lymph node showing that the tumor was composed of monotonous round cells with scant eosinophilic cytoplasm (A, H&E staining, ×200). Tumor cells were positive for CD56 (B, ×100), synaptophysin A (C, ×200), and chromogranin (D, ×200).

Reference

1. Hainsworth JD, Johnson DH, Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site: a newly recognized clinicopathologic entity. Ann Intern Med. 1988; 109:364–371. PMID: 2841895.

2. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol. 2009; 36:52–59. PMID: 19179188.

3. Bajetta E, Catena L, Procopio G, Bichisao E, Ferrari L, Della Torre S, et al. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol. 2005; 16:1374–1380. PMID: 15939719.

4. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006; 24:3548–3554. PMID: 16877720.

5. Boghossian V, Owen ID, Nuli B, Xiao PQ. Neuroendocrine (Merkel cell) carcinoma of the retroperitoneum with no identifiable primary site. World J Surg Oncol. 2007; 5:117. PMID: 17949500.

6. Hisamori S, Okabe H, Yoshizawa A, Sakai Y. A case of long-term recurrence-free poorly differentiated neuroendocrine carcinoma of lymph nodes treated by surgical resection without any chemotherapy. Int J Clin Oncol. 2010; 15:493–496. PMID: 20224882.

7. Kuwabara H, Mori H, Uda H, Takei K, Ishibashi Y, Takatani N. Nodal neuroendocrine (Merkel cell) carcinoma without an identifiable primary tumor. Acta Cytol. 2003; 47:515–517. PMID: 12789943.

8. Ueda J, Aimoto T, Nakamura Y, Hiroi M, Yamahatsu K, Hayakawa T, et al. Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma. Nihon Shokakibyo Gakkai Zasshi. 2010; 107:1941–1946. PMID: 21139363.

9. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999; 81:1351–1355. PMID: 10604732.

10. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001; 92:1101–1107. PMID: 11571721.